Molecular Partners AG - ADR Forecast, price target & analysts
Molecular Partners AG - ADR Target price 2025 - Analyst rating & recommendation
Molecular Partners AG - ADR Classifications & Recommendation:
Molecular Partners AG - ADR Price Target
| Target Price | $9.14 |
| Price | $4.85 |
| Potential |
88.50%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Molecular Partners AG - ADR 2026 .
The average Molecular Partners AG - ADR target price is $9.14.
This is
88.50%
register free of charge
$16.65
243.32%
register free of charge
$5.08
4.80%
register free of charge
|
|
| A rating was issued by 5 analysts: 3 Analysts recommend Molecular Partners AG - ADR to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Molecular Partners AG - ADR stock has an average upside potential 2026 of
88.50%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 7.83 | 5.07 |
| 96.06% | 35.28% | |
| EBITDA Margin | -834.10% | -1,332.81% |
| 1,428.94% | 59.79% | |
| Net Margin | -890.15% | -1,128.80% |
| 1,501.13% | 26.81% |
5 Analysts have issued a sales forecast Molecular Partners AG - ADR 2024 . The average Molecular Partners AG - ADR sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Molecular Partners AG - ADR EBITDA forecast 2024. The average Molecular Partners AG - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
1 Analyst has issued a net profit forecast Molecular Partners AG - ADR 2024 . The average Molecular Partners AG - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.10 | -1.72 |
| 155.26% | 18.10% | |
| P/E | negative | |
| EV/Sales | 2.34 |
1 Analysts have issued a Molecular Partners AG - ADR forecast for earnings per share. The average Molecular Partners AG - ADR <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Molecular Partners AG - ADR stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Molecular Partners AG - ADR...
Current Molecular Partners AG - ADR Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| TD COWEN | Locked ➜ Locked | Locked | Oct 31 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
TD COWEN: Locked ➜ Locked
|
Oct 31 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
